Disclosures for "Fenfluramine in CDKL5 Deficiency Disorder: Primary Efficacy and Safety Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study "
-
Dr. Moseley has received personal compensation for serving as an employee of UCB. Dr. Moseley has received personal compensation for serving as an employee of Neurocrine Biosciences Inc. Dr. Moseley has or had stock in UCB.
-
Nicola Specchio has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Nicola Specchio has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for stoke.
-
Dr. Marsh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia Pharmacuticals. Dr. Marsh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Stoke Therapeutics. Dr. Marsh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acadia Pharmaceuticals. The institution of Dr. Marsh has received research support from NIH. The institution of Dr. Marsh has received research support from Rett Syndrome Research Trust. The institution of Dr. Marsh has received research support from International Rett Syndrome Foundation. The institution of Dr. Marsh has received research support from Eagles Autism Challenge. The institution of Dr. Marsh has received research support from LouLou Foundation. The institution of Dr. Marsh has received research support from International CDKL5 Resarch Foundation. The institution of Dr. Marsh has received research support from Acadia Pharmaceuticals. The institution of Dr. Marsh has received research support from Marinus. The institution of Dr. Marsh has received research support from Stoke Therapeutics. The institution of Dr. Marsh has received research support from Takeda Pharmaceuticals. Dr. Marsh has received personal compensation in the range of $500-$4,999 for serving as a Grant Review with NIH. Dr. Marsh has received personal compensation in the range of $5,000-$9,999 for serving as a Expert Witness with Department of Human Services. Dr. Marsh has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Medscape.
-
Dr. Devinsky has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Devinsky has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for California Cannabis Enterprises. Dr. Devinsky has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Engage. Dr. Devinsky has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Privateer Holdings. Dr. Devinsky has received personal compensation in the range of $1,000,000+ for serving on a Scientific Advisory or Data Safety Monitoring board for Receptor Holdings. Dr. Devinsky has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Rettco. Dr. Devinsky has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Silver Spike. Dr. Devinsky has received personal compensation in the range of $100,000-$499,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Tevard. Dr. Devinsky has received personal compensation in the range of $1,000,000+ for serving on a Scientific Advisory or Data Safety Monitoring board for Tilray. Dr. Devinsky has received personal compensation in the range of $100,000-$499,999 for serving as an officer or member of the Board of Directors for Engage. Dr. Devinsky has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for Tevard Biosciences. Dr. Devinsky has stock in Engage. Dr. Devinsky has stock in Empatica. Dr. Devinsky has stock in California Cannabis Enterprises. Dr. Devinsky has stock in Empatica. Dr. Devinsky has stock in Silver Spike. Dr. Devinsky has stock in Docklight Brands. Dr. Devinsky has stock in Egg Rock/Papa Barkley. Dr. Devinsky has stock in Leafly. Dr. Devinsky has stock in Left Coast Ventures. Dr. Devinsky has stock in Privateer Holdings. Dr. Devinsky has stock in Receptor Holdings. Dr. Devinsky has stock in Qstate. The institution of Dr. Devinsky has received research support from GW Pharma. The institution of Dr. Devinsky has received research support from Zogenix. The institution of Dr. Devinsky has received research support from PTC Pharma. The institution of Dr. Devinsky has received research support from NIH. The institution of Dr. Devinsky has received research support from DOD. The institution of Dr. Devinsky has received research support from NIH. The institution of Dr. Devinsky has received research support from Epilepsy Foundation. The institution of Dr. Devinsky has received research support from NIH. The institution of Dr. Devinsky has received research support from NIH. The institution of Dr. Devinsky has received research support from NSF. Dr. Devinsky has received intellectual property interests from a discovery or technology relating to health care. Dr. Devinsky has received intellectual property interests from a discovery or technology relating to health care. Dr. Devinsky has received publishing royalties from a publication relating to health care.
-
Angel Aledo-Serrano has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Angel Aledo-Serrano has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Angelini. Angel Aledo-Serrano has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Stoke pharma. Angel Aledo-Serrano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Jazz pharma. Angel Aledo-Serrano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB.
-
Prof. Battaglia has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biocodex. Prof. Battaglia has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB-Pharma. Prof. Battaglia has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB-Pharma. The institution of Prof. Battaglia has received research support from Italian Minister of University and Scientific Research.
-
Dr. Rajaraman has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Marinus Pharmacueticals.
-
Dr. Keough has received personal compensation in the range of $5,000-$9,999 for serving as a Speaker with UCB. Dr. Keough has received personal compensation in the range of $50,000-$99,999 for serving as a Speaker with Jazz Pharmaceuticals. Dr. Keough has received personal compensation in the range of $50,000-$99,999 for serving as a Speaker with SKLSI . Dr. Keough has received personal compensation in the range of $10,000-$49,999 for serving as a Speaker with LivaNova.
-
Mrs. HONDA has received research support from UCB Inc..
-
Renzo Guerrini has nothing to disclose.
-
Author has nothing to disclose
-
Sam Amin has nothing to disclose.
-
Ms. Jaksha has nothing to disclose.
-
Dr. St. Wecker has received personal compensation for serving as an employee of UCB. Dr. St. Wecker has received personal compensation for serving as an employee of Zogenix, Inc.. Dr. St. Wecker has stock in Zogenix.
-
Mr. Kilgallen has received personal compensation for serving as an employee of UCB. Mr. Kilgallen has stock in UCB.
-
Dr. Dickson has nothing to disclose.
-
Dr. Sullivan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biocodex. Dr. Sullivan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for UCB. Dr. Sullivan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Ceribell. Dr. Sullivan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Xenon. Dr. Sullivan has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Epilepsy Study Consortium. Dr. Sullivan has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neuropace. Dr. Sullivan has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for Various firms. Dr. Sullivan has stock in Harmony.